Skip to main content
SpringerLink
Log in

Joining the dots: Answers

  • Clinical Quiz
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

References

  1. Fucile C, Mattioli F, Marini V, Gregori M, Sonzogni A, Martelli A, Maximova N (2018) What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis. Ther Clin Risk Manag 14:1649–1655. https://doi.org/10.2147/TCRM.S170761

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rodríguez-Soriano J, Vallo A (1990) Renal tubular acidosis. Pediatr Nephrol 4:268–275. https://doi.org/10.1007/BF00857675

    Article  PubMed  Google Scholar 

  3. Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A (2010) Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother 44:219–221. https://doi.org/10.1345/aph.1M440

    Article  PubMed  Google Scholar 

  4. Sakurai A, Tamura A, Onishi Y, Ishikawa T (2005) Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother 6:2455–2473. https://doi.org/10.1517/14656566.6.14.2455

    Article  CAS  PubMed  Google Scholar 

  5. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237–2244. https://doi.org/10.1200/JCO.2005.03.0239

    Article  CAS  PubMed  Google Scholar 

  6. Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868–1873. https://doi.org/10.1111/j.1349-7006.2011.02030.x

    Article  CAS  PubMed  Google Scholar 

  7. Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J (2014) Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol Ther 141:92–116. https://doi.org/10.1016/j.pharmthera.2013.09.002

    Article  CAS  PubMed  Google Scholar 

  8. Benoit-Biancamano MO, Connelly J, Villeneuve L, Caron P, Guillemette C (2009) Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos 37:322–329

    Article  CAS  Google Scholar 

  9. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491. https://doi.org/10.1126/science.286.5439.487

    Article  CAS  PubMed  Google Scholar 

  10. Cao K, Ren G, Lu C, Wang Y, Tan Y, Zhou J, Zhang Y, Lu Y, Li N, Chen X, Zhao D (2020) ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects. Eur J Clin Pharmacol 76:51–59. https://doi.org/10.1007/s00228-019-02775-1

    Article  CAS  PubMed  Google Scholar 

  11. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 118:884–893. https://doi.org/10.1182/blood-2010-11-316646 Erratum in: Blood (2011) 118:5060

    Article  CAS  PubMed  Google Scholar 

  12. Marano M, Bottaro G, Goffredo B, Stoppa F, Pisani M, Marinaro AM, Deodato F, Dionisi-Vici C, Clementi E, Falvella FS (2016) Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis. Eur J Clin Pharmacol 72:247–248. https://doi.org/10.1007/s00228-015-1956-2

    Article  CAS  PubMed  Google Scholar 

  13. Clinical Pharmacogenetics Implementation Consortium (2021) Genes – Drugs. https://cpicpgx.org/genes-drugs. Accessed 20 April 2021

  14. Aycicek A, Koc A, Abuhandan M (2014) Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience. Pediatr Int 56:530–533. https://doi.org/10.1111/ped.12323

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Child Health, Kolkata, India

    Niladri Bose & Rajiv Sinha

  2. Apollo Multi-Specialty Hospitals, Kolkata, India

    Kaustabh Chaudhuri

  3. Birmingham Women’s And Children’s NHS Foundation Trust, Birmingham, UK

    Mordi Muorah

  4. Paediatric Nephrology, Institute of Child Health, Kolkata, India

    Rajiv Sinha

Authors
  1. Niladri Bose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kaustabh Chaudhuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mordi Muorah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rajiv Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajiv Sinha.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This refers to the article that can be found at https://doi.org/10.1007/s00467-021-05394-0.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bose, N., Chaudhuri, K., Muorah, M. et al. Joining the dots: Answers. Pediatr Nephrol 37, 1525–1528 (2022). https://doi.org/10.1007/s00467-021-05415-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-021-05415-y

Keywords

Search

Navigation